Virax Biolabs Group annual stock-based compensation
2022
2023
2024
2025
2026
Virax Biolabs Group Stock-Based Compensation Growth & History (VRAX)
Virax Biolabs Group's stock-based compensation was $130,409 for fiscal 2026.
View full Virax Biolabs Group company overviewVirax Biolabs Group annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | $130,409 | −$234,900 | −64.30% |
| 2025 | 2025-03-31 | $365,309 | −$646,664 | −63.90% |
| 2024 | 2024-03-31 | $1.0M | −$722,628 | −41.66% |
| 2023 | 2023-03-31 | $1.7M | $1.4M | +497.39% |
| 2022 | 2022-03-31 | $290,364 | — | — |
Virax Biolabs Group stock-based compensation trends
Between the periods ended 2022-03-31 and 2026-03-31, Virax Biolabs Group's stock-based compensation decreased from $290,364 to $130,409, a change of −$159,955.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Virax Biolabs Group source filings ↗